美服培酮/米索前列醇
美服培酮/米索前列醇是包括兩種成份的單一複方藥物,主要用於藥物流產[7]。這是懷孕11 周以內的常用墮胎方法之一,但也可在懷孕中期使用[3] [9]。也可治療 12 周以內的早期流產[3]。可以利用妊娠試驗或超聲波檢查確認妊娠是否成功[3]。可以口服或舌下服用[7] [10]。在懷孕前期,通常可以在家中自行使用,可以由家庭醫師直接就診時或透過遠距醫療開立處方;若在妊娠中期,建議住院處理[3] [9]。
組成 | |
---|---|
美服培酮 | 孕激素受體拮抗劑 |
米索前列醇 | Prostaglandin E1 |
臨床資料 | |
商品名 | Mifegymiso,[1] Medabon Combipack,[2] others |
給藥途徑 | 口服、陰道塞劑[3] |
法律規範狀態 | |
法律規範 |
|
副作用包括可能噁心、腹痛和輕度發熱[3]。可能出現子宮痙攣和陰道出血[3]。大量出血、持續妊娠和感染則較罕見[3]。它不會增加精神障礙、乳癌或不孕的風險[3]。藥物含有美服培酮和米索前列醇,前者是一種抗孕激素,會使蛻膜分解,後者是一種前列腺素 E1 ,會促使宮頸成熟和子宮收縮[3]。
美服培酮於 1987 年在法國開始使用,美國則始於 2000 年[11] [12]。此成份的學名藥在 2019 年上市[12]。米索前列醇於 1973 年研發成功[13]。美服培酮/米索前列醇的複方藥名列世界衛生組織基本藥物標準清單[14]。
參考文獻
編輯- ^ Linepharma International Limited. Mifegymiso Product Monograph (PDF). Health Canada. 15 April 2019 [10 September 2023]. (原始內容存檔 (PDF)於22 March 2023). 互聯網檔案館的存檔,存檔日期22 March 2023.
- ^ Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). 3 February 2020 [19 January 2021]. (原始內容存檔於9 June 2021). 互聯網檔案館的存檔,存檔日期9 June 2021.
- ^ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 Macnaughton, H; Nothnagle, M; Early, J. Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion.. American family physician. 15 April 2021, 103 (8): 473–480 [6 December 2023]. PMID 33856168. (原始內容存檔於19 October 2023). 互聯網檔案館的存檔,存檔日期19 October 2023.
- ^ Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). 3 February 2020 [19 January 2021]. (原始內容存檔於9 June 2021). 互聯網檔案館的存檔,存檔日期9 June 2021.
- ^ The Abortion Pill | Get the Facts About Medication Abortion. Planned Parenthood. [2023-08-18]. (原始內容存檔於2023-08-16). 互聯網檔案館的存檔,存檔日期2023-08-16.
- ^ Mifepristone/misoprostol: List of nationally authorised medicinal products (PDF). European Medicines Agency. 14 January 2021 [18 August 2023]. PSUSA/00010378/202005. (原始內容存檔 (PDF)於16 September 2023). 互聯網檔案館的存檔,存檔日期16 September 2023.
- ^ 7.0 7.1 7.2 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. (原始內容存檔於4 June 2023).
- ^ 8.0 8.1 Mifepristone and misoprostol: Recommended regimen. Ipas. [10 September 2023]. (原始內容存檔於22 April 2023). 互聯網檔案館的存檔,存檔日期22 April 2023.
- ^ 9.0 9.1 Gemzell-Danielsson, K; Lalitkumar, S. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management.. Reproductive health matters. May 2008, 16 (31 Suppl): 162-72. PMID 18772097. doi:10.1016/S0968-8080(08)31371-8.
- ^ Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews. May 2022, 2022 (5): CD002855. PMC 9128719 . PMID 35608608. doi:10.1002/14651858.CD002855.pub5.
- ^ Corey, E.J. https://web.archive.org/web/20170908184336/https://books.google.com/books?id=jz2GN6DYoOoC&pg=RA1-PT108
|archiveurl=
缺少標題 (幫助). Mifepristone. John Wiley & Sons. 2012. ISBN 9781118361733. (原始內容存檔於2017-09-08). - ^ 12.0 12.1 Research, Center for Drug Evaluation and. Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation. FDA. 24 March 2023 [10 September 2023]. (原始內容存檔於21 April 2023) (英語).
- ^ Paul, Maureen. https://web.archive.org/web/20151222100701/https://books.google.ca/books?id=iK7xrRr2p9sC&pg=RA1-PT161
|archiveurl=
缺少標題 (幫助). Misoprostol. John Wiley & Sons. 2011 [20 December 2015]. ISBN 9781444358476. (原始內容存檔於22 December 2015). - ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.